ConductScience.org, home

Paper41136631

Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.

Wang X and 4 others. Cancer Immunol Immunother, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study. Papers, record 41136631. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41136631

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
2025
PubMed
Publication types
Journal Article, Comparative Study
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-09-17
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang XXin
2Wu YYaqin
3Huang JJian
4Zong DDan
5He XXia

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Uterine Cervical NeoplasmsMajor topic
Neoplasm Recurrence, LocalMajor topic
Immune Checkpoint InhibitorsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Antibodies, BispecificMajor topic
Humans
Female
Retrospective Studies
Middle Aged
Bevacizumab
Aged
Adult
CTLA-4 Antigen
Prognosis

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82172804National Natural Science Foundation of ChinaPubMed

Source PubMed

Download CSV of grants

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138048793Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.Lancet2024https://conductscience.org/library/papers/38048793PubMed
235636017ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy.Redox Biol2022https://conductscience.org/library/papers/35636017PubMed
339843940First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.Nat Med2025https://conductscience.org/library/papers/39843940PubMed
433661538Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.Cochrane Database Syst Rev2021https://conductscience.org/library/papers/33661538PubMed
536793374Effect of Exosomal lncRNA MALAT1/miR-370-3p/STAT3 Positive Feedback Loop on PI3K/Akt Pathway Mediating Cisplatin Resistance in Cervical Cancer Cells.J Oncol2023https://conductscience.org/library/papers/36793374PubMed
639905663
Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study.
Cancer Control2025https://conductscience.org/library/papers/39905663PubMed
740069710
Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.
BMC Med2025https://conductscience.org/library/papers/40069710PubMed
840293533Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study.Cancer Immunol Immunother2025https://conductscience.org/library/papers/40293533PubMed
939390972The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study.Thorac Cancer2024https://conductscience.org/library/papers/39390972PubMed
1038330795Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.Int Immunopharmacol2024https://conductscience.org/library/papers/38330795PubMed
1140565299Bispecific Antibodies in Solid Tumors: Advances and Challenges.Int J Mol Sci2025https://conductscience.org/library/papers/40565299PubMed
1240713827
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study.
J Hematol Oncol2025https://conductscience.org/library/papers/40713827PubMed
1338448606The present and future of bispecific antibodies for cancer therapy.Nat Rev Drug Discov2024https://conductscience.org/library/papers/38448606PubMed
1439426385
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Lancet2024https://conductscience.org/library/papers/39426385PubMed
1528756902Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).Lancet2017https://conductscience.org/library/papers/28756902PubMed
1634534429Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.N Engl J Med2021https://conductscience.org/library/papers/34534429PubMed
1739492841
Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial.
Ther Adv Med Oncol2024https://conductscience.org/library/papers/39492841PubMed
1840057343Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.Lancet2025https://conductscience.org/library/papers/40057343PubMed
1935747125Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy.J Oncol2022https://conductscience.org/library/papers/35747125PubMed
2019720909Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.J Clin Oncol2009https://conductscience.org/library/papers/19720909PubMed

See all 21 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42022176Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies.MedComm (2020)2026https://conductscience.org/library/papers/42022176PubMed
41373687Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition".Int J Mol Sci2025https://conductscience.org/library/papers/41373687PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41136631

GET https://conductscience.org/api/papers/v1/41136631/references?page=2